The Lancet. Respiratory medicine
Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome.
Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial.
Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
The diagnosis of idiopathic pulmonary fibrosis: current and future approaches.
Challenges in predicting which patients will develop ARDS.
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts.
Acetylcysteine in IPF: the knockout blow?
ARDS in 2015: new clinical directions, new biological insights.
Idiopathic pulmonary fibrosis: continuing to make progress.
